Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2004.08.067 on June 1 2004

Journal of Clinical Oncology, Vol 22, No 13 (July 1), 2004: pp. 2594-2601
© 2004 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gurubhagavatula, S.
Right arrow Articles by Christiani, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gurubhagavatula, S.
Right arrow Articles by Christiani, D. C.
Related Articles
Right arrowRelated Editorial
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non—Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy

Sarada Gurubhagavatula, Geoffrey Liu, Sohee Park, Wei Zhou, Li Su, John C. Wain, Thomas J. Lynch, Donna S. Neuberg, David C. Christiani

From the Departments of Medicine and Surgery, Massachusetts General Hospital; the Departments of Environmental Health, Epidemiology, and Biostatistics, Harvard School of Public Health; and the Dana-Farber/Harvard Cancer Center, Boston, MA

Address reprint requests to David C. Christiani, MD, Department of Environmental Health, Harvard School of Public Health, 665 Huntington Ave, Boston, MA 02115; e-mail: dchristi{at}hsph.harvard.edu

PURPOSE: Platinum agents cause DNA cross-linking and oxidative damage. Genetic polymorphisms of DNA repair genes are associated with differential DNA repair activity and may explain interindividual differences in overall survival after therapy with platinum agents for non–small-cell lung cancer (NSCLC).

METHODS: We used polymerase chain reaction–restriction fragment length polymorphism to evaluate genetic polymorphisms of the XPD (Asp312Asn) and XRCC1 (Arg399Gln) DNA repair genes in 103 patients with stage III (54%) and IV (46%) NSCLC treated with platinum-based chemotherapy.

RESULTS: Median age was 58 years (range, 32 to 77 years), 49% were females, and there were 86 deaths. Median follow-up period was 61.9 months. Median survival time (MST) was 14.9 months; by stage, MST was 28.6 months (IIIA), 16.0 months (IIIB), and 9.3 months (IV). Genotypes were not associated with stage. Increasing numbers of either XPD or XRCC1 variant alleles were associated with shorter overall survival (P = .003 and P = .07, respectively, by log-rank test). Similarly, when we compared combinations of variant alleles across both polymorphisms, we found that a greater number of variant alleles was associated with decreasing overall survival (P = .009, log-rank test). These polymorphisms independently predicted overall survival even after taking into account stage, performance status, and chemotherapy regimen.

CONCLUSION: Genetic polymorphisms in XPD and XRCC1 may be important prognostic factors in platinum-treated patients with advanced NSCLC.

D.C.C. was supported by National Institutes of Health (NIH) grants CA092824, CA74386, and CA90578; S.G. was supported by an NIH grant (5T32 CA71345-07) in Cancer Biology; G.L. was supported by a Doris Duke C.S. Award and a DF/HCC Lung Cancer Clinician Scientist Development Award.

This study was initially presented in the Pharmacogenomics and Cancer Therapy oral presentation session at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • The Use and Development of Germline Polymorphisms in Clinical Oncology
    Heinz-Josef Lenz
    JCO 2004 22: 2519-2521 [Full Text]


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
W. Wu, W. Zhang, R. Qiao, D. Chen, H. Wang, Y. Wang, S. Zhang, G. Gao, A. Gu, J. Shen, et al.
Association of XPD Polymorphisms with Severe Toxicity in Non-Small Cell Lung Cancer Patients in a Chinese Population
Clin. Cancer Res., June 1, 2009; 15(11): 3889 - 3895.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
P. PACETTI, E. GIOVANNETTI, A. MAMBRINI, S. NANNIZZI, M. ORLANDI, R. TARTARINI, A. DEL FREO, M. DEL TACCA, R. DANESI, and M. CANTORE
Single Nucleotide Polymorphisms and Clinical Outcome in Patients with Biliary Tract Carcinoma Treated with Epirubicin, Cisplatin and Capecitabine
Anticancer Res, May 1, 2009; 29(5): 1835 - 1840.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
W.-C. Hsieh, Y.-W. Cheng, C.-J. Lin, M.-C. Chou, C.-Y. Chen, and H. Lee
Prognostic Significance of X-ray Cross-complementing Group 1 T-77C Polymorphism in Resected Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., February 1, 2009; 39(2): 81 - 85.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H.-T. Kim, J.-E. Lee, E.-S. Shin, Y.-K. Yoo, J.-H. Cho, M.-H. Yun, Y.-H. Kim, S.-K. Kim, H.-J. Kim, T.-W. Jang, et al.
Effect of BRCA1 Haplotype on Survival of Non-Small-Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
J. Clin. Oncol., December 20, 2008; 26(36): 5972 - 5979.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Gao, D. K. Price, T. Sissung, E. Reed, and W. D. Figg
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1
Mol. Cancer Ther., May 1, 2008; 7(5): 1246 - 1250.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
J. R. Molina, P. Yang, S. D. Cassivi, S. E. Schild, and A. A. Adjei
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Mayo Clin. Proc., May 1, 2008; 83(5): 584 - 594.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Tibaldi, E. Giovannetti, E. Vasile, V. Mey, A. C. Laan, S. Nannizzi, R. Di Marsico, A. Antonuzzo, C. Orlandini, S. Ricciardi, et al.
Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients
Clin. Cancer Res., March 15, 2008; 14(6): 1797 - 1803.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Hopkins, D. W. Cescon, D. Tse, P. Bradbury, W. Xu, C. Ma, P. Wheatley-Price, J. Waldron, D. Goldstein, F. Meyer, et al.
Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 490 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
P. A. Bradbury, R. S. Heist, M. H. Kulke, W. Zhou, A. L. Marshall, D. P. Miller, L. Su, S. Park, J. Temel, P. Fidias, et al.
A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies
Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 204 - 211.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. O. Park, S.-W. Kim, J. S. Ahn, C. Suh, J. S. Lee, J. S. Jang, E. K. Cho, S. H. Yang, J.-H. Choi, D. S. Heo, et al.
Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non Small-Cell Lung Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5233 - 5239.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Sakano, Y. Hinoda, N. Okayama, Y. Kawai, Y. Korenaga, S. Eguchi, K. Nagao, C. Ohmi, and K. Naito
The association of DNA repair gene polymorphisms with the development and progression of renal cell carcinoma
Ann. Onc., November 1, 2007; 18(11): 1817 - 1827.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Matakidou, R. el Galta, E. L. Webb, M. F. Rudd, H. Bridle, the GELCAPS Consortium, T. Eisen, and R. S. Houlston
Genetic variation in the DNA repair genes is predictive of outcome in lung cancer
Hum. Mol. Genet., October 1, 2007; 16(19): 2333 - 2340.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. F. Giachino, P. Ghio, S. Regazzoni, G. Mandrile, S. Novello, G. Selvaggi, D. Gregori, M. DeMarchi, and G. V. Scagliotti
Prospective Assessment of XPD Lys751Gln and XRCC1 Arg399Gln Single Nucleotide Polymorphisms in Lung Cancer
Clin. Cancer Res., May 15, 2007; 13(10): 2876 - 2881.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Kuptsova, K. J. Kopecky, J. Godwin, J. Anderson, A. Hoque, C. L. Willman, M. L. Slovak, and C. B. Ambrosone
Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials
Blood, May 1, 2007; 109(9): 3936 - 3944.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Bewick, M. S.C. Conlon, and R. M. Lafrenie
Polymorphisms in XRCC1, XRCC3, and CCND1 and Survival After Treatment for Metastatic Breast Cancer
J. Clin. Oncol., December 20, 2006; 24(36): 5645 - 5651.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Brem, D. G. Cox, B. Chapot, N. Moullan, P. Romestaing, J.-P. Gerard, P. Pisani, and J. Hall
The XRCC1 -77T->C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage
Carcinogenesis, December 1, 2006; 27(12): 2469 - 2474.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Sun, Y. Gao, W. Tan, S. Ma, X. Zhang, Y. Wang, Q. Zhang, Y. Guo, D. Zhao, C. Zeng, et al.
Haplotypes in Matrix Metalloproteinase Gene Cluster on Chromosome 11q22 Contribute to the Risk of Lung Cancer Development and Progression
Clin. Cancer Res., December 1, 2006; 12(23): 7009 - 7017.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Quintela-Fandino, R. Hitt, P. P. Medina, S. Gamarra, L. Manso, H. Cortes-Funes, and M. Sanchez-Cespedes
DNA-Repair Gene Polymorphisms Predict Favorable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy
J. Clin. Oncol., September 10, 2006; 24(26): 4333 - 4339.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
T. van der Straaten, D. Kweekel, M. Tiller, J. Bogaartz, and H.-J. Guchelaar
Multiplex Pyrosequencing of Two Polymorphisms in DNA Repair Gene XRCC1
J. Mol. Diagn., September 1, 2006; 8(4): 444 - 448.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. D. Kennedy and A. D. D'Andrea
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
J. Clin. Oncol., August 10, 2006; 24(23): 3799 - 3808.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
X. Wu, J. Gu, T.-T. Wu, S. G. Swisher, Z. Liao, A. M. Correa, J. Liu, C. J. Etzel, C. I. Amos, M. Huang, et al.
Genetic Variations in Radiation and Chemotherapy Drug Action Pathways Predict Clinical Outcomes in Esophageal Cancer
J. Clin. Oncol., August 10, 2006; 24(23): 3789 - 3798.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Monzo, S. Brunet, A. Urbano-Ispizua, A. Navarro, G. Perea, J. Esteve, R. Artells, M. Granell, J. Berlanga, J. M. Ribera, et al.
Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia
Blood, June 15, 2006; 107(12): 4871 - 4879.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ruzzo, F. Graziano, K. Kawakami, G. Watanabe, D. Santini, V. Catalano, R. Bisonni, E. Canestrari, R. Ficarelli, E. T. Menichetti, et al.
Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy
J. Clin. Oncol., April 20, 2006; 24(12): 1883 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Li, M. Frazier, D. B. Evans, K. R. Hess, C. H. Crane, L. Jiao, and J. L. Abbruzzese
Single Nucleotide Polymorphisms of RecQ1, RAD54L, and ATM Genes Are Associated With Reduced Survival of Pancreatic Cancer
J. Clin. Oncol., April 10, 2006; 24(11): 1720 - 1728.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. C. Christiani
Genetic Susceptibility to Lung Cancer
J. Clin. Oncol., April 10, 2006; 24(11): 1651 - 1652.
[Full Text] [PDF]

Home page
 ChestHome page
H. Sugimura and P. Yang
Long-term Survivorship in Lung Cancer: A Review.
Chest, April 1, 2006; 129(4): 1088 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. de las Penas, M. Sanchez-Ronco, V. Alberola, M. Taron, C. Camps, R. Garcia-Carbonero, B. Massuti, C. Queralt, M. Botia, R. Garcia-Gomez, et al.
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients
Ann. Onc., April 1, 2006; 17(4): 668 - 675.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Moreno, F. Gemignani, S. Landi, L. Gioia-Patricola, A. Chabrier, I. Blanco, S. Gonzalez, E. Guino, G. Capella, F. Canzian, et al.
Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer.
Clin. Cancer Res., April 1, 2006; 12(7): 2101 - 2108.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Li, H. Liu, L. Jiao, D. Z. Chang, G. Beinart, R. A. Wolff, D. B. Evans, M. M. Hassan, and J. L. Abbruzzese
Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival.
Cancer Res., March 15, 2006; 66(6): 3323 - 3330.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Komatsu, K. Hiyama, K. Tanimoto, M. Yunokawa, K. Otani, M. Ohtaki, E. Hiyama, J. Kigawa, M. Ohwada, M. Suzuki, et al.
Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers.
Mol. Cancer Ther., March 1, 2006; 5(3): 767 - 775.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Y. Chang, R. Komaki, R. Sasaki, Z. Liao, C. W. Stevens, C. Lu, F. V. Fossella, P. K. Allen, J. D. Cox, M. R. Spitz, et al.
High Mutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage III Non-Small Cell Lung Cancer Treated with Radiotherapy and Chemotherapy
Clin. Cancer Res., April 15, 2005; 11(8): 2894 - 2898.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Gu, H. Zhao, C. P. Dinney, Y. Zhu, D. Leibovici, C. E. Bermejo, H. Barton Grossman, and X. Wu
Nucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer
Clin. Cancer Res., February 15, 2005; 11(4): 1408 - 1415.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Suk, S. Gurubhagavatula, S. Park, W. Zhou, L. Su, T. J. Lynch, J. C. Wain, D. Neuberg, G. Liu, and D. C. Christiani
Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non-Small Cell Lung Cancer Patients
Clin. Cancer Res., February 15, 2005; 11(4): 1534 - 1538.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H.-J. Lenz
The Use and Development of Germline Polymorphisms in Clinical Oncology
J. Clin. Oncol., July 1, 2004; 22(13): 2519 - 2521.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online